Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Elsaghier, A. A. F.
Right arrow Articles by Kibbler, C. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elsaghier, A. A. F.
Right arrow Articles by Kibbler, C. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2002) 49, 423-424
© 2002 The British Society for Antimicrobial Chemotherapy

Correspondence

Resistance to teicoplanin developing during treatment of methicillin-resistant Staphylococcus aureus infection

Ashraf A. F. Elsaghiera, Hazel M. Auckenb, Jeremy M. Hamilton-Millera, Stephen Shawa and Christopher C. Kibblera,*

a Royal Free and University College Medical School, University College London, Royal Free Campus, Department of Medical Microbiology, London NW3 2PF; b PHLS Central Public Health Laboratory, Laboratory of Hospital Infection, London NW9 5HT, UK

Sir,

The emergence of vancomycin resistance in Staphylococcus aureus1 has caused considerable concern in Japan and the USA, but there have been few reports from the UK. We have detected reduced susceptibility to teicoplanin and vancomycin during the treatment of two methicillin-resistant Staphylococcus aureus (MRSA) infections with teicoplanin. Both patients died. We present these two cases in order to draw attention to this emerging problem and to emphasize the clinical significance of this form of resistance.

The first patient, a 66-year-old man, was admitted for . . . [Full Text of this Article]

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
P.-R. Hsueh, L.-J. Teng, W.-H. Chen, H.-J. Pan, M.-L. Chen, S.-C. Chang, K.-T. Luh, and F.-Y. Lin
Increasing Prevalence of Methicillin-Resistant Staphylococcus aureus Causing Nosocomial Infections at a University Hospital in Taiwan from 1986 to 2001
Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1361 - 1364.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
K. R. Fiebelkorn, S. A. Crawford, M. L. McElmeel, and J. H. Jorgensen
Practical Disk Diffusion Method for Detection of Inducible Clindamycin Resistance in Staphylococcus aureus and Coagulase-Negative Staphylococci
J. Clin. Microbiol., October 1, 2003; 41(10): 4740 - 4744.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Cepeda, S. Hayman, T. Whitehouse, C. C. Kibbler, D. Livermore, M. Singer, and A. P. R. Wilson
Teicoplanin resistance in methicillin-resistant Staphylococcus aureus in an intensive care unit
J. Antimicrob. Chemother., September 1, 2003; 52(3): 533 - 534.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. J. Manuel, A. Tuck, A. Lowes, and A. Pallett
Detection of teicoplanin resistance in UK EMRSA-17 strains
J. Antimicrob. Chemother., December 1, 2002; 50(6): 1089 - 1090.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Weinbren and K. Struthers
Emergence of Staphylococcus aureus (MRSA) with reduced susceptibility to teicoplanin during therapy
J. Antimicrob. Chemother., August 1, 2002; 50(2): 306 - 307.
[Full Text] [PDF]